51
|
Comprehensive Geriatric Assessment and Caring for the Older Person with Cancer. Semin Oncol Nurs 2017; 33:440-448. [DOI: 10.1016/j.soncn.2017.08.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
52
|
Dotan E. Adjusting Our Current Practice to Better Care for the Older Patient With Cancer. J Oncol Pract 2017; 13:103-104. [PMID: 28972828 DOI: 10.1200/jop.2016.019687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
53
|
Fagard K, Casaer J, Wolthuis A, Flamaing J, Milisen K, Lobelle JP, Wildiers H, Kenis C. Value of geriatric screening and assessment in predicting postoperative complications in patients older than 70 years undergoing surgery for colorectal cancer. J Geriatr Oncol 2017; 8:320-327. [DOI: 10.1016/j.jgo.2017.07.008] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Revised: 06/14/2017] [Accepted: 07/20/2017] [Indexed: 01/19/2023]
|
54
|
O'Donovan A, Leech M, Gillham C. Assessment and management of radiotherapy induced toxicity in older patients. J Geriatr Oncol 2017; 8:421-427. [PMID: 28739158 DOI: 10.1016/j.jgo.2017.07.001] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 05/19/2017] [Accepted: 07/06/2017] [Indexed: 02/07/2023]
Abstract
Radiotherapy is an attractive treatment option for older adults, especially where surgery and chemotherapy pose too great a risk. Radiotherapy toxicity may be divided into acute/early and late effects of treatment. The latter may have limited relevance to an older patient with competing causes of mortality due to significant comorbidity. Altered fractionation regimes have been employed in numerous sites, with no significant toxicity impact. These offer greater convenience in the elderly, especially those with limited social support or in active caregiving roles. As radiotherapy toxicity is site specific, it's important to assess baseline function via Comprehensive Geriatric Assessment (CGA), and any pre-existing comorbidities that may influence toxicity. With modern radiotherapy technology and capabilities, these are less of an issue and radiotherapy is a very suitable treatment option for the older adult. When evaluating the literature on toxicity in older patients, it's important to recognise that older studies do not represent modern day radiotherapy techniques and capabilities. Advanced technology may simultaneously deliver enhanced target coverage and reduced toxicity. More research is required related to the predictive power of CGA in linking radiotherapy toxicity to frailty. What little evidence exists shows that CGA has a role in treatment of older patients with radiotherapy and that, in general, radiotherapy appears to be well tolerated in older adults. The purpose of this review is to provide a broad overview of the mechanisms of normal tissue reactions to radiotherapy and how radiation induced toxicity may affect older patients.
Collapse
Affiliation(s)
- Anita O'Donovan
- Applied Radiation Therapy Trinity (ARTT), School of Medicine, Trinity College Dublin, Ireland.
| | - Michelle Leech
- Applied Radiation Therapy Trinity (ARTT), School of Medicine, Trinity College Dublin, Ireland.
| | - Charles Gillham
- Saint Luke's Radiation Oncology Network, Highfield Rd., Rathgar, Dublin 6, Ireland.
| |
Collapse
|
55
|
Schmidt H, Boese S, Lampe K, Jordan K, Fiedler E, Müller-Werdan U, Wienke A, Vordermark D. Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). J Geriatr Oncol 2017; 8:262-270. [DOI: 10.1016/j.jgo.2017.04.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 03/08/2017] [Accepted: 04/20/2017] [Indexed: 01/02/2023]
|
56
|
Abstract
The incidence of brain tumors in the elderly population has increased over the last few decades. Current treatment includes surgery, radiotherapy and chemotherapy, but the optimal management of older patients with brain tumors remains a matter of debate, since aggressive radiation treatments in this population may be associated with high risks of neurological toxicity and deterioration of quality of life. For such patients, a careful clinical status assessment is mandatory both for clinical decision making and for designing randomized trials to adequately evaluate the optimal combination of radiotherapy and chemotherapy. Several randomized studies have demonstrated the efficacy and safety of chemotherapy for patients with glioblastoma or lymphoma; however, the use of radiotherapy given in association with chemotherapy or as salvage therapy remains an effective treatment option associated with survival benefit. Stereotactic techniques are increasingly used for the treatment of patients with brain metastases and benign tumors, including pituitary adenomas, meningiomas and acoustic neuromas. Although no randomized trials have proven the superiority of SRS over other radiation techniques in older patients with brain metastases or benign brain tumors, data extracted from recent randomized studies and large retrospective series suggest that SRS is an effective approach in such patients associated with survival advantages and toxicity profile similar to those observed in young adults. Future trials need to investigate the optimal radiation techniques and dose/fractionation schedules in older patients with brain tumors with regard to clinical outcomes, neurocognitive function, and quality of life.
Collapse
Affiliation(s)
- Giuseppe Minniti
- Department of Neurological Sciences, IRCCS Neuromed, Via Atinense, Pozzilli, (IS), Italy. .,UPMC San Pietro FBF, Radiotherapy Center, Rome, Italy.
| | | | | | | |
Collapse
|
57
|
Antonio M, Saldaña J, Carmona-Bayonas A, Navarro V, Tebé C, Nadal M, Formiga F, Salazar R, Borràs JM. Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making? Oncologist 2017; 22:934-943. [PMID: 28487465 DOI: 10.1634/theoncologist.2016-0462] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 01/25/2017] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND The challenge when selecting elderly patients with colorectal cancer (CRC) for adjuvant therapy is to estimate the likelihood that death from other causes will preclude cancer events from occurring. The aim of this paper is to evaluate whether comprehensive geriatric assessment (CGA) can predict survival and cancer-specific mortality in elderly CRC patients candidates for adjuvant therapy. MATERIAL AND METHODS One hundred ninety-five consecutive patients aged ≥75 with high-risk stage II and stage III CRC were prospectively included from May 2008 to May 2015. All patients underwent CGA, which evaluated comorbidity, polypharmacy, functional status, geriatric syndromes, mood, cognition, and social support. According to CGA results, patients were classified into three groups-fit, medium-fit, and unfit-to receive standard therapy, adjusted treatment, and best supportive care, respectively. We recorded survival and cause of death and used the Fine-Gray regression model to analyze competing causes of death. RESULTS Following CGA, 85 (43%) participants were classified as fit, 57 (29%) as medium-fit, and 53 (28%) as unfit. The univariate 5-year survival rates were 74%, 52%, and 27%. Sixty-one (31%) patients died due to cancer progression (53%), non-cancer-related cause (46%), and unknown reasons (1%); there were no toxicity-related deaths. Fit and medium-fit participants were more likely to die due to cancer progression, whereas patients classified as unfit were at significantly greater risk of non-cancer-related death. CONCLUSION CGA showed efficacy in predicting survival and discriminating between causes of death in elderly patients with high-risk stage II and stage III resected CRC, with potential implications for shaping the decision-making process for adjuvant therapies. IMPLICATIONS FOR PRACTICE Adjuvant therapy in elderly patients with colorectal cancer is controversial due to the high risk for competing events among these patients. In order to effectively select older patients for adjuvant therapy, we have to weigh the risk of cancer-related mortality and the potential survival benefits with treatment against the patient's life expectancy, irrespective of cancer. This prospective study focused on the prognostic value of geriatric assessment for survival using a competing-risk analysis approach, providing an important contribution on the treatment decision-making process and helping clinicians to identify elderly patients who might benefit from adjuvant chemotherapy among those who will not.
Collapse
Affiliation(s)
- Maite Antonio
- Medical Oncology Department, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català d'Oncologia (ICO)-Hospital Duran i Reynals, University of Barcelona, Spain
| | - Juana Saldaña
- Medical Oncology Department, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català d'Oncologia (ICO)-Hospital Duran i Reynals, University of Barcelona, Spain
| | | | - Valentín Navarro
- Research Clinical Unit, Institut Català d'Oncologia (ICO)-Hospital Duran I Reynals, Barcelona, Spain
| | - Cristian Tebé
- Statisical Assessment Service, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) and Universitat Rovira i Virgili, Spain
| | - Marga Nadal
- Research Management Unit, Institut Català d'Oncologia (ICO)-Hospital Duran I Reynals, Barcelona, Spain
| | - Francesc Formiga
- Internal Medicine Service, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, University of Barcelona, Spain
| | - Ramon Salazar
- Medical Oncology Department, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català d'Oncologia (ICO)-Hospital Duran i Reynals, University of Barcelona, Spain
| | - Josep Maria Borràs
- Department of Clinical Sciences, University of Barcelona and Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Spain
| |
Collapse
|
58
|
Abstract
BACKGROUND In general, cancer is a disease of aging, and palliative care is an essential step in the management of cancer in patients who are older. The goal of this article is to review common symptoms of cancer and oncology treatment and their management. METHODS The pertinent medical literature was reviewed. RESULTS The scope of palliative care includes personalized cancer treatment. This involves choosing treatment options that best fit the needs of each individual patient. Balancing treatment benefits and risks may be challenging in older patients, many of whom have limited life expectancies and decreased functional reserves. The benefits of treatment may diminish, and the risks of such treatment options increase with age. Thus, the first step toward personalized treatment includes determining physiological age, which is best estimated with a comprehensive geriatric assessment. Prevention of common complications, which include neutropenia and mucositis, allows the administration of treatment in full and effective doses. Fatigue is a chronic symptom related to cancer and its treatment and may lead to functional dependence and an increased risk of death. Fatigue might be prevented by daily exercise even during treatment. Other symptoms include pain and feelings of memory loss. CONCLUSIONS The scope of palliative care encompasses more issues that symptom management and, for this reason, palliative care should be provided once the diagnosis of cancer is established. Determining treatment goals is essential to improve the treatment experience. Symptom management is similar in older and young patients, but symptoms in the older population may be associated with more frequent and severe complications. Many options exist to prevent and ameliorate the complications of oncology treatment in the aged. However, more studies should be conducted on the long-term care of older patients who have survived cancer.
Collapse
|
59
|
Lubeek SFK, Borgonjen RJ, van Vugt LJ, Olde Rikkert MG, van de Kerkhof PCM, Gerritsen MJP. Improving the applicability of guidelines on nonmelanoma skin cancer in frail older adults: a multidisciplinary expert consensus and systematic review of current guidelines. Br J Dermatol 2016; 175:1003-1010. [PMID: 27484632 DOI: 10.1111/bjd.14923] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/31/2016] [Indexed: 01/09/2023]
Abstract
BACKGROUND Balancing treatment decisions in frail older adults with nonmelanoma skin cancer (NMSC) can be challenging. Clinical practice guidelines (CPGs) could provide assistance. OBJECTIVES To collect and prioritize items related to frail older adults with NMSC for integration into CPGs and to assess the current extent of this integration. METHODS Items were collected and prioritized by a multidisciplinary working group (29 members) using a modified Delphi procedure and a five-point Likert scale. To assess current integration of these items in CPGs, a systematic review was subsequently performed by two independent reviewers using five medical databases (PubMed, Embase, Cochrane Library, SUMsearch and Trip Database), websites of guideline developers/databases, and (inter)national dermatological societies. RESULTS Prioritization of a final 13-item list showed that 'limited life expectancy' (4·5 ± 0·9) and 'treatment goals other than cure' (4·4 ± 0·7) were most desired to be integrated into CPGs; both were included in six (46%) of the CPGs found (n = 13). Attention to 'tumour characteristics' and 'comorbidities' were included in CPGs most often (100% and 77%, respectively). CONCLUSIONS More attention to items related to frail older adults in NMSC CPGs is broadly desired, but CPG integration of these items is currently limited. More integration might stimulate more holistic, personalized and patient-centred care in frail older adults.
Collapse
Affiliation(s)
- S F K Lubeek
- Department of Dermatology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands.
| | - R J Borgonjen
- Department of Dermatology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands
| | - L J van Vugt
- Department of Dermatology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands
| | - M G Olde Rikkert
- Department of Geriatrics, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands
| | - P C M van de Kerkhof
- Department of Dermatology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands
| | - M J P Gerritsen
- Department of Dermatology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands
| |
Collapse
|
60
|
Cohen HJ, Smith D, Sun CL, Tew W, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Filo J, Katheria V, Hurria A. Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer 2016; 122:3865-3872. [PMID: 27529755 DOI: 10.1002/cncr.30269] [Citation(s) in RCA: 117] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 07/26/2016] [Accepted: 07/28/2016] [Indexed: 11/08/2022]
Abstract
BACKGROUND Frailty has been suggested as a construct for oncologists to consider in treating older cancer patients. Therefore, the authors assessed the potential of creating a deficit-accumulation frailty index (DAFI) from a largely self-administered comprehensive geriatric assessment (CGA). METHODS Five hundred patients aged ≥65 years underwent a CGA before receiving chemotherapy. A DAFI was constructed, resulting in a 51-item scale, and cutoff values were examined for patients in the robust/nonfrail (cutoff value, 0.0 < 0.2), prefrail (cutoff value, 0.2 < 0.35), and frail (cutoff value, ≥ 0.35) groups. RESULTS Two hundred and fifty patients (50%) were nonfrail, 197 (39%) were prefrail, and 52 (11%) were frail. Older patients (aged ≥ 80 years) and those who had lower education, were living alone, and had higher stage disease were associated with prefrail/frail status. Prefrail/frail patients were more likely to have grade ≥3 toxicity but not to have a dose delay or reduction, and they were more likely to discontinue drug and be hospitalized. The association with grade ≥3 toxicity was attenuated by controlling for a toxicity risk calculator, but the other outcomes were not. CONCLUSIONS A deficit-accumulation frailty index can be constructed from a CGA in older patients with cancer and can indicate the frailty status of the population. The frailty status so determined is associated both with outcomes likely because of chemotherapy toxicity and with those likely because of age-related physiologic and functional deficits and thus can be useful in the overall assessment of the patient. Cancer 2016;122:3865-3872. © 2016 American Cancer Society.
Collapse
Affiliation(s)
- Harvey Jay Cohen
- Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina
| | - David Smith
- QIMR Berghofer Medical Research Institute, Royal Brisbane and Women's Hospital, Brisbane City, Queensland, Australia
| | - Can-Lan Sun
- City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California
| | - William Tew
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Supriya G Mohile
- Department of Medicine, University of Rochester Medical Center, Rochester, New York
| | - Cynthia Owusu
- University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio
| | - Heidi D Klepin
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
| | - Cary P Gross
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Stuart M Lichtman
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Ajeet Gajra
- Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York.,Veterans Administration Medical Center, Syracuse, New York
| | - Julie Filo
- City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California
| | - Vani Katheria
- City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California
| | - Arti Hurria
- City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California
| | | |
Collapse
|
61
|
Tew WP. Ovarian cancer in the older woman. J Geriatr Oncol 2016; 7:354-61. [PMID: 27499341 DOI: 10.1016/j.jgo.2016.07.008] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Revised: 05/02/2016] [Accepted: 07/18/2016] [Indexed: 02/08/2023]
Abstract
Ovarian cancer is the seventh most common cancer in women worldwide and accounts for nearly 4% of all new cases of cancer in women. Almost half of all patients with ovarian cancer are over the age of 65 at diagnosis, and over 70% of deaths from ovarian cancer occur in this same age group. As the population ages, the number of older women with ovarian cancer is increasing. Compared to younger women, older women with ovarian cancer receive less surgery and chemotherapy, develop worse toxicity, and have poorer outcomes. They are also significantly under-represented in clinical trials and thus application of standard treatment regimens can be challenging. Performance status alone has been shown to be an inadequate tool to predict toxicity of older patients from chemotherapy. Use of formal geriatric assessment tools is a promising direction for stratifying older patients on trials. Elderly-specific trials, adjustments to the eligibility criteria, modified treatment regimens, and interventions to decrease morbidities in the vulnerable older population should be encouraged.
Collapse
|
62
|
Bluhm M, Connell CM, Janz N, Bickel K, DeVries R, Silveira M. Oncologists’ End of Life Treatment Decisions. J Appl Gerontol 2016. [DOI: 10.1177/0733464815595510] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: Optimal treatment decisions for older end-stage cancer patients are complicated, and are influenced by oncologists’ attitudes and beliefs about older patients. Nevertheless, few studies have explored oncologists’ perspectives on how patient age affects their treatment decisions. Methods: In-depth interviews were conducted with 17 oncologists to examine factors that influence their chemotherapy decisions for adults with incurable cancer near death. Transcripts of recorded interviews were coded and content analyzed. Results: Oncologists identified patient age as a key factor in their chemotherapy decisions. They believed older adults were less likely to want or tolerate treatment, and felt highly motivated to treat younger patients. Discussion: Qualitative analysis of in-depth interviews resulted in a nuanced understanding of how patient age influences oncologists’ chemotherapy decisions. Such understanding may inform practice efforts aimed at enhancing cancer care at the end of life for older patients.
Collapse
Affiliation(s)
| | | | | | - Kathleen Bickel
- Veterans Affairs White River Junction Medical Center, Geisel School of Medicine at Dartmouth, USA
| | | | | |
Collapse
|
63
|
Magnuson A, Allore H, Cohen HJ, Mohile SG, Williams GR, Chapman A, Extermann M, Olin RL, Targia V, Mackenzie A, Holmes HM, Hurria A. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research. J Geriatr Oncol 2016; 7:242-8. [PMID: 27197915 DOI: 10.1016/j.jgo.2016.02.007] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 12/28/2015] [Accepted: 02/20/2016] [Indexed: 10/21/2022]
Abstract
Older adults with cancer represent a complex patient population. Geriatric assessment (GA) is recommended to evaluate the medical and supportive care needs of this group. "GA with management" is a term encompassing the resultant medical decisions and interventions implemented in response to vulnerabilities identified on GA. In older, non-cancer patients, GA with management has been shown to improve a variety of outcomes, such as reducing functional decline and health care utilization. However, the role of GA with management in the older adult with cancer is less well established. Rigorous clinical trials of GA with management are necessary to develop an evidence base and support its use in the routine oncology care of older adults. At the recent U-13 conference, "Design and Implementation of Intervention Studies to Improve or Maintain Quality of Survivorship in Older and/or Frail Adults with Cancer," a session was dedicated to developing research priorities in GA with management. Here we summarize identified knowledge gaps in GA with management studies for older patients with cancer and propose areas for future research.
Collapse
Affiliation(s)
| | | | | | | | - Grant R Williams
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | | | | - Rebecca L Olin
- University of California San Francisco, San Francisco, CA, USA
| | | | | | - Holly M Holmes
- The University of Texas Health Science Center McGovern Medical School, Houston, TX, USA
| | | |
Collapse
|
64
|
Presley CJ, Dotan E, Soto-Perez-de-Celis E, Jatoi A, Mohile SG, Won E, Alibhai S, Kilari D, Harrison R, Klepin HD, Wildes TM, Mustian K, Demark-Wahnefried W. Gaps in nutritional research among older adults with cancer. J Geriatr Oncol 2016; 7:281-92. [PMID: 27197919 PMCID: PMC4969118 DOI: 10.1016/j.jgo.2016.04.006] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2015] [Revised: 03/03/2016] [Accepted: 04/18/2016] [Indexed: 01/01/2023]
Abstract
Nutritional issues among older adults with cancer are an understudied area of research despite significant prognostic implications for treatment side effects, cancer-specific mortality, and overall survival. In May of 2015, the National Cancer Institute and the National Institute on Aging co-sponsored a conference focused on future directions in geriatric oncology research. Nutritional research among older adults with cancer was highlighted as a major area of concern as most nutritional cancer research has been conducted among younger adults, with limited evidence to guide the care of nutritional issues among older adults with cancer. Cancer diagnoses among older adults are increasing, and the care of the older adult with cancer is complicated due to multimorbidity, heterogeneous functional status, polypharmacy, deficits in cognitive and mental health, and several other non-cancer factors. Due to this complexity, nutritional needs are dynamic, multifaceted, and dependent on the clinical scenario. This manuscript outlines the proceedings of this conference including knowledge gaps and recommendations for future nutritional research among older adults with cancer. Three common clinical scenarios encountered by oncologists include (1) weight loss during anti-cancer therapy, (2) malnutrition during advanced disease, and (3) obesity during survivorship. In this manuscript, we provide a brief overview of relevant cancer literature within these three areas, knowledge gaps that exist, and recommendations for future research.
Collapse
Affiliation(s)
- Carolyn J Presley
- Yale Cancer Center/Yale University School of Medicine, New Haven, CT, USA.
| | - Efrat Dotan
- Fox Chase Cancer Center, Philadelphia, PA, USA
| | - Enrique Soto-Perez-de-Celis
- Cancer Care in the Elderly Clinic, Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | | | - Supriya G Mohile
- James Wilmot Cancer Center at the University of Rochester, Rochester, NY, USA
| | - Elizabeth Won
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Shabbir Alibhai
- Department of Medicine,University Health Network and University of Toronto,Canada
| | - Deepak Kilari
- Froedtert Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Robert Harrison
- SCOREboard,University of Rochester Medical Center, Rochester, NY, USA
| | - Heidi D Klepin
- Wake Forrest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA
| | - Tanya M Wildes
- Washington University School of Medicine, St. Louis, MO, USA
| | - Karen Mustian
- James Wilmot Cancer Center at the University of Rochester, Rochester, NY, USA
| | | |
Collapse
|
65
|
Karuturi M, Wong ML, Hsu T, Kimmick GG, Lichtman SM, Holmes HM, Inouye SK, Dale W, Loh KP, Whitehead MI, Magnuson A, Hurria A, Janelsins MC, Mohile S. Understanding cognition in older patients with cancer. J Geriatr Oncol 2016; 7:258-69. [PMID: 27282296 PMCID: PMC4969091 DOI: 10.1016/j.jgo.2016.04.004] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 02/01/2016] [Accepted: 04/18/2016] [Indexed: 02/04/2023]
Abstract
Cancer and neurocognitive disorders, such as dementia and delirium, are common and serious diseases in the elderly that are accompanied by high degree of morbidity and mortality. Furthermore, evidence supports the under-diagnosis of both dementia and delirium in older adults. Complex questions exist regarding the interaction of dementia and delirium with cancer, beginning with guidelines on how best measure disease severity, the optimal screening test for either disorder, the appropriate level of intervention in the setting of abnormal findings, and strategies aimed at preventing the development or progression of either process. Ethical concerns emerge in the research setting, pertaining to the detection of cognitive dysfunction in participants, validity of consent, disclosure of abnormal results if screening is pursued, and recommended level of intervention by investigators. Furthermore, understanding the ways in which comorbid cognitive dysfunction and cancer impact both cancer and non-cancer-related outcomes is essential in guiding treatment decisions. In the following article, we will discuss what is presently known of the interactions of pre-existing cognitive impairment and delirium with cancer. We will also discuss identified deficits in our knowledge base, and propose ways in which innovative research may address these gaps.
Collapse
Affiliation(s)
- Meghan Karuturi
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Melisa L Wong
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
| | - Tina Hsu
- The Ottawa Hospital Cancer Center, Ottawa, Canada
| | | | | | - Holly M Holmes
- University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Sharon K Inouye
- Harvard Medical School, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA; Aging Brain Center, Hebrew SeniorLife, Boston, MA, USA
| | | | - Kah P Loh
- University of Rochester Medical Center, Rochester, NY, USA
| | | | | | - Arti Hurria
- Comprehensive Cancer Center, City of Hope, Duarte, CA, USA
| | | | | |
Collapse
|
66
|
Spoelstra SL, Given CW, Sikorskii A, Coursaris CK, Majumder A, DeKoekkoek T, Schueller M, Given BA. Proof of Concept of a Mobile Health Short Message Service Text Message Intervention That Promotes Adherence to Oral Anticancer Agent Medications: A Randomized Controlled Trial. Telemed J E Health 2016; 22:497-506. [PMID: 26716365 PMCID: PMC4892193 DOI: 10.1089/tmj.2015.0126] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Revised: 09/09/2015] [Accepted: 09/09/2015] [Indexed: 11/12/2022] Open
Abstract
INTRODUCTION This multisite, randomized controlled trial assigned 75 adult cancer patients prescribed an oral anticancer agent to either an experimental group that received daily text messages for adherence for 21 days plus usual care or a control group that received usual care. MATERIALS AND METHODS Measures were administered at baseline, weekly (Weeks 1-8), and at exit (Week 9). A satisfaction survey was conducted following the intervention. Acceptability, feasibility, and satisfaction were examined. Primary outcomes were adherence and symptoms. Secondary outcomes were depressive symptoms, self-efficacy, cognition, physical function, and social support. Mixed or general linear models were used for the analyses comparing trial groups. Effect sizes (ES) were estimated to gauge clinical significance. RESULTS Regarding acceptability, 57.2% (83 of 145) of eligible patients consented, 88% (n = 37 of 42) receiving text messages read them most or all of the time, and 90% (n = 38) were satisfied. The differences between experimental and control groups' ES were 0.29 for adherence, 0.21 for symptom severity, and 0.21 for symptom interference, and differences were not statistically significant. Furthermore, perceived social support was higher (p = 0.04; ES = 0.54) in the experimental group. CONCLUSIONS Proof of concept and preliminary efficacy of a mobile health intervention using text messages to promote adherence for patients prescribed oral anticancer agents were demonstrated. Patients accepted and had high satisfaction with the intervention, and adherence improved after the intervention. Text messages show promise. Additional research is needed prior to use in practice.
Collapse
Affiliation(s)
| | - Charles W. Given
- Department of Family Medicine, Michigan State University, East Lansing, Michigan
| | - Alla Sikorskii
- Department of Statistics and Probability, Michigan State University, East Lansing, Michigan
| | - Constantinos K. Coursaris
- Department of Telecommunication, Information Studies, and Media, Michigan State University, East Lansing, Michigan
| | - Atreyee Majumder
- Department of Statistics and Probability, Michigan State University, East Lansing, Michigan
| | - Tracy DeKoekkoek
- College of Nursing, Michigan State University, East Lansing, Michigan
| | - Monica Schueller
- College of Nursing, Michigan State University, East Lansing, Michigan
| | - Barbara A. Given
- College of Nursing, Michigan State University, East Lansing, Michigan
| |
Collapse
|
67
|
Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, Feng T, Smith D, Sun CL, De Glas N, Cohen HJ, Katheria V, Doan C, Zavala L, Levi A, Akiba C, Tew WP. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. J Clin Oncol 2016; 34:2366-71. [PMID: 27185838 DOI: 10.1200/jco.2015.65.4327] [Citation(s) in RCA: 427] [Impact Index Per Article: 53.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Older adults are at increased risk for chemotherapy toxicity, and standard oncology assessment measures cannot identify those at risk. A predictive model for chemotherapy toxicity was developed (N = 500) that consisted of geriatric assessment questions and other clinical variables. This study aims to externally validate this model in an independent cohort (N = 250). PATIENTS AND METHODS Patients age ≥ 65 years with a solid tumor, fluent in English, and who were scheduled to receive a new chemotherapy regimen were recruited from eight institutions. Risk of chemotherapy toxicity was calculated (low, medium, or high risk) on the basis of the prediction model before the start of chemotherapy. Chemotherapy-related toxicity was captured (grade 3 [hospitalization indicated], grade 4 [life threatening], and grade 5 [treatment-related death]). Validation of the prediction model was performed by calculating the area under the receiver-operating characteristic curve. RESULTS The study sample (N = 250) had a mean age of 73 years (range, 65 to 94 [standard deviation, 5.8]). More than one half of patients (58%) experienced grade ≥ 3 toxicity. Risk of toxicity increased with increasing risk score (36.7% low, 62.4% medium, 70.2% high risk; P < .001). The area under the curve of the receiver-operating characteristic curve was 0.65 (95% CI, 0.58 to 0.71), which was not statistically different from the development cohort (0.72; 95% CI, 0.68 to 0.77; P = .09). There was no association between Karnofsky Performance Status and chemotherapy toxicity (P = .25). CONCLUSION This study externally validated a chemotherapy toxicity predictive model for older adults with cancer. This predictive model should be considered when discussing the risks and benefits of chemotherapy with older adults.
Collapse
Affiliation(s)
- Arti Hurria
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands.
| | - Supriya Mohile
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Ajeet Gajra
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Heidi Klepin
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Hyman Muss
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Andrew Chapman
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Tao Feng
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - David Smith
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Can-Lan Sun
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Nienke De Glas
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Harvey Jay Cohen
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Vani Katheria
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Caroline Doan
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Laura Zavala
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Abrahm Levi
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - Chie Akiba
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| | - William P Tew
- Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands
| |
Collapse
|
68
|
|
69
|
Socioeconomic Considerations and Shared-Care Models of Cancer Care for Older Adults. Clin Geriatr Med 2016; 32:35-44. [DOI: 10.1016/j.cger.2015.08.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
70
|
Kenis C, Heeren P, Decoster L, Van Puyvelde K, Conings G, Cornelis F, Cornette P, Moor R, Luce S, Libert Y, Van Rijswijk R, Jerusalem G, Rasschaert M, Langenaeken C, Baitar A, Specenier P, Geboers K, Vandenborre K, Debruyne PR, Vanoverbeke K, Van den Bulck H, Praet JP, Focan C, Verschaeve V, Nols N, Goeminne JC, Petit B, Lobelle JP, Flamaing J, Milisen K, Wildiers H. A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and Facilitators. J Nutr Health Aging 2016; 20:60-70. [PMID: 26728935 DOI: 10.1007/s12603-016-0677-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVES The aim of this study is to describe a large-scale, Belgian implementation project about geriatric assessment (=GA) in daily oncology practice and to identify barriers and facilitators for implementing GA in this setting. Design / setting / participants: The principal investigator of every participating hospital (n=22) was invited to complete a newly developed questionnaire with closed- and open-ended questions. The closed-ended questions surveyed how GA was implemented. The open-ended questions identified barriers and facilitators for the implementation of GA in daily oncology practice. Descriptive statistics and conventional content analysis were performed as appropriate. RESULTS Qualifying criteria (e.g. disease status and cancer type) for GA varied substantially between hospitals. Thirteen hospitals (59.1%) succeeded to screen more than half of eligible patients. Most hospitals reported that GA data and follow-up data had been collected in almost all screened patients. Implementing geriatric recommendations and formulating new geriatric recommendations at the time of follow-up are important opportunities for improvement. The majority of identified barriers were organizational, with high workload, lack of time or financial/staffing problems as most cited. The most cited facilitators were all related to collaboration. CONCLUSION Interventions to improve the implementation of GA in older patients with cancer need to address a wide range of factors, with organization and collaboration as key elements. All stakeholders, seeking to improve the implementation of GA in older patients with cancer, should consider and address the identified barriers and facilitators.
Collapse
Affiliation(s)
- C Kenis
- Hans Wildiers, Herestraat 49, 3000 Leuven, Belgium, Tel.: +32 16 34 69 20, Fax.: +32 16 34 69 01, E-mail address:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med 2015; 12:284-91. [PMID: 26779365 PMCID: PMC4706522 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 11/19/2015] [Indexed: 02/06/2023] Open
Abstract
In the coming years life expectancy is expected to increase and with this the percentage of the population above age 65 will grow. Patients above 65 make up more than two thirds of those currently diagnosed with gastrointestinal malignancies. Available evidence based medicine does not focus on the average patient, above the age 70, encountered in every day practice. Most guidelines and clinical trials are not designed to take into account the special considerations needed when treating the elderly such as functional status, comorbidities, polypharmacy, life expectancy, and social support. The majority of available data is based on retrospective reviews or subset analyses of larger studies where the elderly represent a fraction of the studied population. This review focuses on the toxicities and tolerability of current standard therapies for non-colorectal gastrointestinal malignancies, including gastroesophageal, pancreatic, bile duct and hepatocellular cancers in the elderly. With careful patient selection and geriatric assessment the elderly can safely benefit from standard therapies offered to younger patients.
Collapse
Affiliation(s)
- Avni M Desai
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 11725, USA
| | - Stuart M Lichtman
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 11725, USA
| |
Collapse
|
72
|
Abstract
Bladder cancer is a disease of older patients who often have multiple comorbidities. Although cisplatin-based combination chemotherapy is the standard of care in the neoadjuvant and metastatic settings, outcomes remain poor, and approximately half of patients are ineligible for cisplatin where treatment options are severely limited. Recent comprehensive genome sequencing studies have defined the mutational spectra of high-grade urothelial carcinoma of the bladder. Although there is a high prevalence of potentially actionable genomic alterations, whether these events represent true oncogenic vulnerabilities has yet to be confirmed. Given the demographics and genetics, we propose that bladder cancer represents an ideal model to study the potential of targeted therapy in older patients who are too often unable to receive cisplatin-based therapy and where novel treatment strategies are desperately needed.
Collapse
Affiliation(s)
- Matthew I Milowsky
- From the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - William Y Kim
- From the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
| |
Collapse
|
73
|
Balducci L, Dolan D. Chronic Lymphocytic Leukemia in the Elderly: Epidemiology and Proposed Patient-Related Approach. Cancer Control 2015; 22:3-6. [DOI: 10.1177/107327481502204s02] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Affiliation(s)
- Lodovico Balducci
- Senior Adult Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | - Dawn Dolan
- Pharmacy Service, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| |
Collapse
|
74
|
Gridelli C, Balducci L, Ciardiello F, Di Maio M, Felip E, Langer C, Lilenbaum RC, Perrone F, Senan S, de Marinis F. Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2015; 16:325-33. [DOI: 10.1016/j.cllc.2015.02.006] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Revised: 02/18/2015] [Accepted: 02/26/2015] [Indexed: 12/29/2022]
|
75
|
Baitar A, Kenis C, Moor R, Decoster L, Luce S, Bron D, Van Rijswijk R, Rasschaert M, Langenaeken C, Jerusalem G, Lobelle JP, Flamaing J, Milisen K, Wildiers H. Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicentre prospective study. J Geriatr Oncol 2015; 6:401-10. [PMID: 26296908 DOI: 10.1016/j.jgo.2015.07.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Revised: 05/12/2015] [Accepted: 07/22/2015] [Indexed: 01/08/2023]
Abstract
PURPOSE The main objective of this study was to describe geriatric recommendations based on a geriatric assessment (GA) and to evaluate the implementation of these recommendations. PATIENTS AND METHODS A two-step approach of screening followed by a GA was implemented in nine hospitals in Belgium. Patients ≥ 70 years were included at diagnosis or at disease progression/relapse. Concrete geriatric recommendations were systematically documented and reported to the treating physicians and consisted of referrals to professional health care workers. Patient charts were reviewed after one month to verify which geriatric recommendations have been performed. RESULTS From August 2011 to July 2012, 1550 patients were included for analysis. The median age was 77 (range: 70-97) and 57.0% were female. A solid tumour was diagnosed in 91.4% and a haematological malignancy in 8.6%. Geriatric screening with the G8 identified 63.6% of the patients for GA (n=986). A median of two geriatric recommendations (range: 1-6) were given for 76.2% (95%CI: 73.4-78.8) of the evaluable patients (n=710). A median of one geriatric recommendation (range: 1-5) was performed in 52.1% (95%CI: 48.4-55.8) of the evaluable patients (n=689). In general, 460 or 35.3% (95%CI: 32.8-38.0) of all the geriatric recommendations were performed. Geriatric recommendations most frequently consisted of referrals to the dietician (60.4%), social worker (40.3%), and psychologist (28.9%). CONCLUSION This implementation study provides insight into GA-based recommendations/interventions in daily oncology practice. Geriatric recommendations were given in about three-fourths of patients. About one-third of all geriatric recommendations were performed in approximately half of these patients.
Collapse
Affiliation(s)
- Abdelbari Baitar
- Department of Medical Oncology, ZNA Middelheim, Antwerp, Belgium
| | - Cindy Kenis
- Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium
| | - Ramona Moor
- Department of Medical Oncology, Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium
| | - Lore Decoster
- Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - Sylvie Luce
- Department of Medical Oncology, University Hospital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Dominique Bron
- Department of Hematology, Institut Jules Bordet (ULB), Brussels, Belgium
| | | | - Marika Rasschaert
- Department of Medical Oncology, Iridium Cancer Network Antwerp, St. Augustinus, Wilrijk, Belgium
| | - Christine Langenaeken
- Department of Medical Oncology, Iridium Cancer Network Antwerp, AZ Klina, Brasschaat, Belgium
| | - Guy Jerusalem
- Department of Medical Oncology, Centre Hospitalier Universitaire Sart Tilman, Liege, Belgium
| | | | - Johan Flamaing
- Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
| | - Koen Milisen
- Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Public Health and Primary Care, Health Services and Nursing Research, KU Leuven, Leuven, Belgium
| | - Hans Wildiers
- Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium.
| |
Collapse
|
76
|
Spoelstra SL, Given CW, Sikorskii A, Majumder A, Schueller M, Given BA. Treatment with oral anticancer agents: symptom severity and attribution, and interference with comorbidity management. Oncol Nurs Forum 2015; 42:80-8. [PMID: 25490974 DOI: 10.1188/15.onf.42-01p] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE/OBJECTIVES To evaluate the prevalence, severity, and attribution of symptoms, as well as the interference with management of comorbidities, in patients who have been prescribed oral anticancer agents (OAs). DESIGN Descriptive exploratory study. SETTING A comprehensive cancer center and two community-based oncology programs in the midwestern United States. SAMPLE 30 adults undergoing OA treatment. METHODS Five phone interviews were conducted during eight weeks. Linear mixed effects and generalized estimating equations were used to examine symptoms and interference over time. MAIN RESEARCH VARIABLES Symptoms and comorbid conditions. FINDINGS The mean age of participants was 65.1 years. Fifteen participants were female, 25 were Caucasian, and 23 had comorbidities. Twenty-one patients had late-stage cancer, and rates of adherence were 90%. Fatigue, sleep disturbance, and numbness or tingling in hands and feet were highly prevalent symptoms. Younger age was associated with higher symptom severity (p < 0.01) and interference (p = 0.01). Patients with more comorbidities tended to report higher symptom severity. Simultaneous IV chemotherapy was not a predictor of symptom severity or interference over age and comorbidity. Symptoms were most frequently attributed to cancer and its treatment. Patients with a greater number of comorbidities were more likely to include comorbidities in symptom attribution and reported interference from the OA with managing comorbid conditions. CONCLUSIONS Symptoms may be more severe in patients prescribed OAs who are younger and have comorbid conditions. More comorbidities and absence of simultaneous IV chemotherapy increased the likelihood of inclusion of chronic conditions in symptom attribution. Patients reported that OA treatment interfered with comorbidity management. IMPLICATIONS FOR NURSING Nurses need to take comorbidities into account when caring for patients prescribed OAs because the chronic conditions may influence symptom severity and the ability to manage symptoms.
Collapse
Affiliation(s)
| | - Charles W Given
- Department of Family Medicine, Michigan State University in East Lansing
| | - Alla Sikorskii
- Department of Statistics and Probability, Michigan State University in East Lansing
| | - Atreyee Majumder
- Department of Statistics and Probability, Michigan State University in East Lansing
| | | | - Barbara A Given
- College of Nursing, Michigan State University in East Lansing
| |
Collapse
|
77
|
Abstract
Plasma cell myeloma (PCM) is a hematologic malignancy that primarily affects the elderly. Approximately two-thirds of patients are aged 65 years or older at diagnosis. Major advances in testing, treatment, and supportive care have resulted in substantial improvement in overall survival in younger, standard-risk, PCM patients over the past 3 decades. However, this positive impact progressively diminishes with advancing age, with some studies showing no improvement in survival outcomes in the elderly. Slow improvement in survival for elderly PCM patients is likely multifactorial, influenced by factors such as age-related physiologic changes, increased comorbidities, decreased treatment tolerance, socioeconomic barriers, and possible differences in disease biology. The standard approach of basing treatment decisions on age and performance status does not account for this complexity, and can be insufficient to determine the risks and benefits of treatment. Comprehensive geriatric assessment (CGA) produces a more thorough iteration of the factors influencing an individual's treatment risk, and can potentially identify targets for intervention to lower risk. Ongoing studies are looking at developing and refining the tools available for risk screening and assessment. Treating elderly PCM patients with novel agent-based regimens with or without autologous stem cell transplantation has improved response rates and survival in some studies, but elderly PCM patients have benefitted less than their younger counterparts from recent advances in PCM treatment. Personalizing treatment decisions, based on predictions of risk, determined by geriatric assessment, and response, determined by precision medicine (our understanding of the genetic, molecular, and cellular pathways that drive an individual's cancer) will help maximize the benefit and minimize the risk of PCM treatment for each patient. Continued evaluation of new strategies and treatments for PCM in clinical trials specifically designed for elderly patients is needed to continue to improve outcomes for elderly PCM patients in the future.
Collapse
|
78
|
Lichtman SM. Polypharmacy: Geriatric Oncology Evaluation Should Become Mainstream. J Clin Oncol 2015; 33:1422-3. [DOI: 10.1200/jco.2014.60.3548] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Stuart M. Lichtman
- Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY
| |
Collapse
|
79
|
Lakhanpal R, Yoong J, Joshi S, Yip D, Mileshkin L, Marx GM, Dunlop T, Hovey EJ, Della Fiorentina SA, Venkateswaran L, Tattersall MH, Liew S, Field K, Singhal N, Steer CB. Geriatric assessment of older patients with cancer in Australia—A multicentre audit. J Geriatr Oncol 2015; 6:185-93. [DOI: 10.1016/j.jgo.2015.03.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Revised: 01/26/2015] [Accepted: 03/04/2015] [Indexed: 12/27/2022]
|
80
|
Abstract
BACKGROUND Data relating to cancer treatment in the older patient population are limited because older individuals have been under-represented in clinical trials. The goal of this review was to establish which factors hinder the participation of older individuals to clinical trials and to examine possible solutions. METHODS The literature relating to cancer treatment in the older patient population was reviewed. RESULTS The benefit of systemic cancer treatment may decrease with age, and risks may be increased due to reduced life expectancy and reduced tolerance of stress in the older population. Therefore, a multipronged approach is recommended for clinical studies in these patients, including phase 2 studies limited to persons 70 years of age and older, stratification by life expectancy and predicted treatment tolerance in phase 3 studies, and registration studies to establish predictive variables for treatment-related toxicity in older individuals. CONCLUSIONS A combination of prospective and registration studies may supply adequate information to study cancer treatments in the older patient population.
Collapse
Affiliation(s)
- Lodovico Balducci
- Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA.
| |
Collapse
|
81
|
O'Donovan A, Mohile SG, Leech M. Expert consensus panel guidelines on geriatric assessment in oncology. Eur J Cancer Care (Engl) 2015; 24:574-89. [PMID: 25757457 DOI: 10.1111/ecc.12302] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/29/2015] [Indexed: 12/27/2022]
Abstract
Despite consensus guidelines on best practice in the care of older patients with cancer, geriatric assessment (GA) has yet to be optimally integrated into the field of oncology in most countries. There is a relative lack of consensus in the published literature as to the best approach to take, and there is a degree of uncertainty as to how integration of geriatric medicine principles might optimally predict patient outcomes. The aim of the current study was to obtain consensus on GA in oncology to inform the implementation of a geriatric oncology programme. A four-round Delphi process was employed. The Delphi method is a structured group facilitation process, using multiple iterations to gain consensus on a given topic. Consensus was reached on the optimal assessment method and interventions required for the commonly employed domains of GA. Other aspects of GA, such as screening methods and age cut-off for assessment, represented a higher degree of disagreement. The expert panel employed in this study clearly identified the criteria that should be included in a clinical geriatric oncology programme. In the absence of evidence-based guidelines, this may prove useful in the care of older cancer patients.
Collapse
Affiliation(s)
- A O'Donovan
- Applied Radiation Therapy Trinity (ARTT), Trinity College Dublin, Ireland
| | - S G Mohile
- James Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
| | - M Leech
- Applied Radiation Therapy Trinity (ARTT), Trinity College Dublin, Ireland
| |
Collapse
|
82
|
Lycke M, Pottel L, Boterberg T, Ketelaars L, Wildiers H, Schofield P, Weller D, Debruyne P. Integration of geriatric oncology in daily multidisciplinary cancer care: the time is now. Eur J Cancer Care (Engl) 2015; 24:143-6. [DOI: 10.1111/ecc.12301] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/20/2015] [Indexed: 11/28/2022]
Affiliation(s)
- M. Lycke
- Cancer Centre; General Hospital Groeninge; Kortrijk Belgium
| | - L. Pottel
- Cancer Centre; General Hospital Groeninge; Kortrijk Belgium
| | - T. Boterberg
- Department of Radiation Oncology; Ghent University Hospital; Ghent Belgium
| | - L. Ketelaars
- Department of Psycho-oncology; General Hospital Groeninge; Kortrijk Belgium
| | - H. Wildiers
- Department of General Medical Oncology & Leuven Cancer Institute; Leuven University Hospital; Leuven Belgium
| | - P. Schofield
- Centre for Positive Ageing; University of Greenwich; London UK
| | - D. Weller
- Centre for Population Health Sciences; University of Edinburgh; Edinburgh UK
| | - P.R. Debruyne
- Cancer Centre; General Hospital Groeninge; Kortrijk Belgium
- Centre for Positive Ageing; University of Greenwich; London UK
| |
Collapse
|
83
|
Balducci L. Systemic treatment of gastric and esophageal adenocarcinoma in elderly patients. J Gastrointest Oncol 2015; 6:75-8. [PMID: 25642340 DOI: 10.3978/j.issn.2078-6891.2014.093] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Accepted: 08/15/2014] [Indexed: 12/14/2022] Open
Abstract
This article explores the treatment of cancer of the stomach and of the lower esophagus in older individuals. The incidence of both malignancies increases with age and, at present, the biology of the diseases, including sensitivity to chemotherapy, does not seem to change with age. The treatment of these cancers in patients 70 and over includes assessment of life expectancy secondary to physiologic age and evaluation of the individual's tolerance to stress. For this purpose a comprehensive geriatric assessment (CGA) is the best validated instrument. For individuals whose life expectancy without cancer exceeds that with cancer, the estimate of the risk of chemotherapy complications may reveal those patients in need of additional care and those patients in whom the risk of treatment may exceed the potential benefits. All older individuals receiving chemotherapy may need adjustment of the doses to the glomerular filtration rate, support with myelopoietic growth factors, and special care to prevent severe and irreversible neurotoxicity.
Collapse
Affiliation(s)
- Lodovico Balducci
- Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL 33618, USA
| |
Collapse
|
84
|
Sun SX, Hollenbeak CS, Leung AM. Deviation from the Standard of Care for Early Breast Cancer in the Elderly: What are the Consequences? Ann Surg Oncol 2014; 22:2492-9. [PMID: 25515198 DOI: 10.1245/s10434-014-4290-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Indexed: 11/18/2022]
Abstract
BACKGROUND For elderly patients with early-stage breast cancer, the standards of care often are not strictly followed due to either clinician biases or patient preferences. The authors hypothesized that forgoing radiation and lymph node (LN) staging for elderly patients with early-stage breast cancer would have a negative impact on survival. METHODS From the Surveillance, Epidemiology, and End Results Program database, 53,619 women older than 55 years with stage 1 breast cancer who underwent breast conservation surgery were identified. Analyses were performed to compare the characteristics and outcomes of patients who received the standards of care with LN sampling and radiation and those of patients who did not, with control used for confounders. To account for selection bias from covariate imbalance, propensity score matching was performed. Survival was analyzed using the Kaplan-Meier method. RESULTS Older patients were less likely to receive radiation and LN sampling. These standards of care were associated with improved overall survival rates of 15.8 and 27.1 % after 10 years, respectively (p ≤ 0.0001). This survival advantage persisted after propensity score matching, with a 7.4 % higher survival rate for patients who received radiation and a 16.8 % higher survival rate for those who underwent LN staging (p < 0.0001). Lymph node sampling and radiation therapy also conferred a statistically significant improvement in breast cancer-specific survival, with 1.3 and 2.6 % lower mortality rates respectively in the radiated and LN biopsy groups (p < 0.0001). CONCLUSIONS As patients age, they are less likely to receive the standard of care for stage 1 breast cancer. Even after controlling for other factors, the study showed that failure to adhere to the standards of LN sampling and radiation therapy may have a negative impact in survival.
Collapse
Affiliation(s)
- Susie X Sun
- Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA, USA
| | | | | |
Collapse
|
85
|
Owusu C, Berger NA. Comprehensive geriatric assessment in the older cancer patient: coming of age in clinical cancer care. ACTA ACUST UNITED AC 2014; 11:749-762. [PMID: 25642321 DOI: 10.2217/cpr.14.72] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Cancer care at the extremes of life, in the young and the old, is characterized by unique issues associated with pediatrics and geriatric medicine, accentuated by the special vulnerabilities of these groups. In response to these needs, the field of pediatric oncology has been well honed to deal with the special problems associated with juvenile cancer patients. While most adult oncologists consider themselves well prepared to deal with older cancer patients, the current expansion of the geriatric population - their variable levels of fitness, frailty and vulnerability, the fact that cancer is primarily a disease of older adults, the significant expansion of agents and approaches to treat cancer, as well as their resultant toxicities and complications - has led to the development of specialized geriatric oncologists. Moreover, the special characteristics and needs of these patients have led to the evolution of new guidelines for evaluation, management and the conduct of research in older patients with cancer.
Collapse
Affiliation(s)
- Cynthia Owusu
- Hematology-Oncolog Division, Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA ; Department of Genetics, Case Western Reserve University, Cleveland, OH 44106, USA ; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA ; University Hospitals Case Medical Center, Cleveland, OH 44106, USA
| | - Nathan A Berger
- Hematology-Oncolog Division, Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA ; Department of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA ; Department of Genetics, Case Western Reserve University, Cleveland, OH 44106, USA ; Center for Science, Health and Society, Case Western Reserve University, Cleveland, OH 44106, USA ; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA ; University Hospitals Case Medical Center, Cleveland, OH 44106, USA
| |
Collapse
|
86
|
Sattar S, Alibhai SMH, Wildiers H, Puts MTE. How to implement a geriatric assessment in your clinical practice. Oncologist 2014; 19:1056-68. [PMID: 25187477 PMCID: PMC4200997 DOI: 10.1634/theoncologist.2014-0180] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 07/17/2014] [Indexed: 12/21/2022] Open
Abstract
Cancer is a disease that mostly affects older adults. Other health conditions, changes in functional status, and use of multiple medications change the risks and benefits of cancer treatment for older adults. Several international organizations, such as the International Society of Geriatric Oncology, the European Organization for Research and Treatment of Cancer, recommend the conduct of a geriatric assessment (GA) for older adults with cancer to help select the most appropriate treatment and identify any underlying undetected medical, functional, and psychosocial issues that can interfere with treatment. The aim of this review is to describe what a GA is and how to implement it in daily clinical practice for older adults with cancer in the oncology setting. We provide an overview of commonly used tools. Key considerations in performing the GA include the resources available (staff, space, and time), patient population (who will be assessed), what GA tools to use, and clinical follow-up (who will be responsible for using the GA results for developing care plans and who will provide follow-up care). Important challenges in implementing GA in clinical practice include not having easy and timely access to geriatric expertise, patient burden of the additional hospital visits, and establishing collaboration between the GA team and oncologists regarding expectations of the population referred for GA and expected outcomes of the GA. Finally, we provide some possible interventions for problems identified during the GA.
Collapse
Affiliation(s)
- Schroder Sattar
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada; Department of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, Ontario, Canada; Department of Medical Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Shabbir M H Alibhai
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada; Department of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, Ontario, Canada; Department of Medical Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Hans Wildiers
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada; Department of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, Ontario, Canada; Department of Medical Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Martine T E Puts
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada; Department of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, Ontario, Canada; Department of Medical Oncology, University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
87
|
Abstract
Cancer is common in older adults and the approach to cancer treatment and supportive measures in this age group is continuously evolving. Incorporating geriatric assessment (GA) into the care of the older patient with cancer has been shown to be feasible and predictive of outcomes, and there are unique aspects of the traditional geriatric domains that can be considered in this population. Geriatric assessment-guided interventions can also be developed to support patients during their treatment course. There are several existing models of incorporating geriatrics into oncology care, including a consultative geriatric assessment, geriatrician "embedded" within an oncology clinic and primary management by a dual-trained geriatric oncologist. Although a geriatrician or geriatric oncologist leads the geriatric assessment, is it truly a multidisciplinary assessment, and often includes evaluation by a physical therapist, occupational therapist, pharmacist, social worker and nutritionist.
Collapse
Affiliation(s)
- A Magnuson
- University of Rochester Medical Center, Rochester, NY
| | - W Dale
- University of Rochester Medical Center, Rochester, NY
| | - S Mohile
- University of Rochester Medical Center, Rochester, NY
| |
Collapse
|
88
|
How I treat ovarian cancer in older women. J Geriatr Oncol 2014; 5:223-9. [DOI: 10.1016/j.jgo.2014.06.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Revised: 04/29/2014] [Accepted: 06/02/2014] [Indexed: 11/17/2022]
|
89
|
Kim DH, Schneeweiss S. Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations. Pharmacoepidemiol Drug Saf 2014; 23:891-901. [PMID: 24962929 DOI: 10.1002/pds.3674] [Citation(s) in RCA: 96] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 05/02/2014] [Accepted: 06/02/2014] [Indexed: 12/17/2022]
Abstract
PURPOSE Geriatric frailty is a common syndrome of older adults that is characterized by increased vulnerability to adverse health outcomes and influences treatment choice. Pharmacoepidemiologic studies that rely on administrative claims data in older adults are limited by confounding due to unmeasured frailty. A claims-based frailty score may be useful to minimize confounding by frailty in such databases. We provide an overview of definitions and measurement of frailty, evaluated the claims-based models of frailty in literature, and recommend ways to improve frailty adjustment in claims analysis. METHODS We searched MEDLINE and EMBASE from inception to April 2014, without language restriction, to identify claims-based multivariable models that predicted frailty or its related outcome, disability. We critically appraised their approach, including population, predictor selection, outcome definition, and model performance. RESULTS Of 152 reports, three models were identified. One model that predicted poor functional status using healthcare service claims in a representative sample of community-dwelling and institutionalized older adults showed an excellent discrimination (C statistic, 0.92). The other two models that predicted disability using either diagnosis codes or prescription claims alone in institutionalized or frail adults had limited generalizability and modest model performance. None of the models have been applied to reduce confounding bias in pharmacoepidemiologic studies of drug therapy. CONCLUSIONS We found little research conducted on development and application of a claims-based frailty index for confounding adjustment in pharmacoepidemiologic studies in older adults. More research is needed to advance this innovative, potentially useful approach by incorporating the expertise from aging research.
Collapse
Affiliation(s)
- Dae Hyun Kim
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | | |
Collapse
|
90
|
Wheeler AA, Nicholl MB. Age Influences Likelihood of Pancreatic Cancer Treatment, but not Outcome. World J Oncol 2014; 5:7-13. [PMID: 29147371 PMCID: PMC5649822 DOI: 10.14740/wjon789w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/26/2014] [Indexed: 11/14/2022] Open
Abstract
Background Pancreatic cancer (PanCA) is predominantly diagnosed in elderly patients; nevertheless, a significant number of young patients are affected. We hypothesized more aggressive treatment of young PanCA patients would result in better overall survival (OS). Methods A retrospective review of our institutional cancer database identified subjects for inclusion. Age 50 years was selected to stratify patients into age groups. Results Of 309 PanCA patients, 54 (17%) were ≤ 50 years old. Exocrine cancer was the most common histology (90%). Patients ≤ 50 years old were more likely to have endocrine cancer (22% vs. 7%, P = 0.001). There was no difference in stage or curative intent surgery between age groups. Despite patients ≤ 50 years old receiving more chemotherapy (61% vs. 41%, P = 0.007) and radiotherapy (28% vs. 15%, P = 0.03), there was no difference in OS (24.1 months vs. 14.1 months, P = 0.08). When only exocrine cancers were considered, there was no difference between young and old patients regarding stage, grade, location or surgery. Exocrine cancer patients ≤ 50 years old received more chemotherapy (67% vs. 42%, P = 0.003) and radiation therapy (36% vs. 17%, P = 0.004), but there was no difference in OS. Conclusions A substantial number of PanCA patients are ≤ 50 years old. Patients ≤ 50 years old received more treatment but did not have improved OS. Significant improvements in PanCA survival await development of new treatment strategies.
Collapse
Affiliation(s)
- Andrew A Wheeler
- Department of Surgery, University of Missouri, Columbia, MO, USA
| | - Michael B Nicholl
- Department of Surgery, University of Missouri, Columbia, MO, USA.,Division of Surgical Oncology, University of Missouri, Columbia, MO, USA.,Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, USA
| |
Collapse
|